
Claims

1. A compound of formula (I), or the pharmaceutically acceptable salts thereof or the crystalline hydrate thereof or the solvate thereof or the prodrug thereof:



(I)



wherein,

R_1 is selected from hydrogen, deuterium, cyano, C_{1-6}acyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, carbamoyl, hydroxymethyl;

R_2 is selected from OR_3, C_{1-6}alkoxy;

R_3 is selected from hydrogen, C_{1-20}alkanoyl, aminoC_{1-20}alkanoyl, C_{1-6}alkylamino-C_{1-6}alkanoyl, C_{1-6}alkoxyC_{1-6}alkyl, α-amino acid, and the carboxyl of the α-amino acid is attached to the hydroxyl on the furan ring via ester bond;

R_4 is selected from hydrogen, deuterium, halogen;

R_5 is selected from R_3,  ,  ;

R_6 is selected from amino, hydroxy, NHOH, $NHCOOR_{12}$;

R_7 is selected from hydrogen, deuterium, halogen;

R_8 is selected from hydrogen, deuterium, halogen, cyano;

X is selected from $-CH_2-$, $-CD_2-$;

R_9 is C_{6-20}aryl;

R_{10} is C_{1-18}alkyl;

R_{12} is C_{1-20}alkyl;

M is each independently selected from hydrogen, metal, or protonated organic amines.

2. The compound of formula (I) of claim 1, or the pharmaceutically acceptable salts thereof or the crystalline hydrate thereof or the solvate thereof or the prodrug thereof, wherein,



R_1 is cyano;

R_2 is selected from OR_3, C_{1-6}alkoxy;

R_3 is selected from hydrogen, C_{1-20}alkanoyl, aminoC_{1-20}alkanoyl,

C_{1-6}alkylamino-C_{1-6}alkanoyl, C_{1-6}alkoxyC_{1-6}alkyl, α-amino acid, and the carboxyl of the α-amino acid is attached to the hydroxyl on the furan ring via ester bond;

R_4 is hydrogen;

R_5 is selected from R_3,  ,  ;

R_6 is amino;

R_7 is hydrogen;

R_8 is selected from hydrogen, deuterium, halogen, cyano;

X is selected from $-CH_2-$, $-CD_2-$;

R_9 is C_{6-20}aryl;

R_{10} is C_{1-18}alkyl;

M is each independently selected from hydrogen, metal, or protonated organic amines.

3. The compound of formula (I) of claim 1, or the pharmaceutically acceptable salts thereof or the crystalline hydrate thereof or the solvate thereof or the prodrug thereof, wherein,

R_1 is cyano;

R_2 is selected from OR_3, C_{1-6}alkoxy;

R_3 is selected from hydrogen, C_{1-20}alkanoyl, aminoC_{1-20}alkanoyl;

R_4 is hydrogen;

R_5 is selected from C_{1-20}alkanoyl, aminoC_{1-20}alkanoyl;


R_6 is amino;


R_7 is hydrogen;


R_8 is selected from hydrogen, deuterium, halogen;


X is selected from $-CH_2-$, $-CD_2-$.


4. The compound of formula (I) claim 1, or the pharmaceutically acceptable salts thereof or the crystalline hydrate thereof or the solvate thereof or the prodrug thereof, wherein the compound is any one of compounds selected from the following group, or the combination thereof:



A1



A2



A3



A4



A5



A7



A9



A10



A11



A12



A28



A35



A36



A49



A50



A51



A52



A53



A54



A55



A56



A57



A58



A60



A62



A64



A66



A69



A70



A71



A72



A73


A74



A75


A76



A77




A78




A79




A80




A82




A83




A84




A85




A86




A87




A88




A89




A102




A103




A104




A105




A106




A107





A108



A112


A113
A114
A115
A116
A117
A118
A119
A120
A121
A122
A123
A124
A125
A126
A127
A128
A129
A130
A131
A132
A133
A134
A135
A136
A137
A138
A139
A140
A141
A142
A143
A144
A145
A146
A147
A148
A149
A150
A151
A152


A153
A154
A155
A156
A157
A158
A159
A160
A161
A162
A163
A164
A165
A166
A167
A168
A169
A170
A171
A172
A173
A174
A175
A176
A177
A178
A179
A180
A181
A182
A183
A184
A185
A186
A187
A188
A189
A190
A191
A192




5. The compound of formula (I) of claim 4, or the pharmaceutically acceptable salts thereof or the crystalline hydrate thereof or the solvate thereof or the prodrug thereof, wherein the compound is any one of the compounds as follows, or combinations thereof:

A1, A5, A9, A10, A11, A12, A28, A35, A36, A49, A50, A51, A52, A53, A54, A55, A57, A58, A69, A70, A71, A72, A73, A74, A75, A76, A77, A78, A79, A80, A84, A87, A88, A89, A102, A105, A106, A107, A108, A113, A114, A115, A116, A117, A118, A119, A120, A121, A122, A123, A124, A125, A126, A127, A128, A129, A130, A131, A132, A133, A134, A135, A136, A137, A138, A139, A140, A141,

A142, A143, A144, A145, A146, A147, A148, A149, A150, A151, A152, A153, A154, A155, A156, A157, A158, A159, A160, A161, A162, A163, A164, A165, A166, A167, A168, A169, A170, A171, A172, A173, A174, A175, A176, A177, A178, A179, A180, A181, A182, A183, A184, A185, A186, A187, A188, A189, A190, A191, A192, A193, A194, A195, A196, A197, A198, A201, A202, A206, A208, A209, A212, A213, A214, A215, A216, A218, A219, A221, or the combination thereof.

6. A use of an active ingredient or a formulation containing the said active ingredient, wherein the active ingredient is a compound of formula (I) or the pharmaceutically acceptable salts thereof or the crystalline hydrate thereof or the solvate thereof or the prodrug thereof:



(I)



wherein,

R_1 is selected from hydrogen, deuterium, cyano, C_{1-6}acyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, carbamoyl, hydroxymethyl;

R_2 is selected fromOR_3, C_{1-6}alkyl;

R_3 is selected from hydrogen, C_{1-20}alkanoyl;

R_4 is selected from hydrogen, deuterium;

R_5 is selected from R_3,  ,  ;

R_6 is selected from amino, hydroxy, NHOH, $NHCOOR_{12}$;

R_7 is selected from hydrogen, deuterium, halogen;

R_8 is selected from hydrogen, deuterium, halogen, cyano;

X is selected from $-CH_2-$, $-CD_2-$;

R_9 is selected from C_{6-20}aryl;

R_{10} is selected from C_{1-18}alkyl;

R_{12} is selected from C_{1-20}alkyl;

M is each independently selected from hydrogen, metal, or protonated organic amines

and the active ingredient or the formulation containing the said active ingredient, is used for preparing (a) inhibitors for inhibiting viral replication; and/or (b) medicaments for treating and/or preventing, alleviating diseases associated with viral infections.

7. The use of Claim 6, wherein the virus is selected from:

(1) coronavirus infecting human: severe acute respiratory syndrome coronavirus (SARS-CoV), 2019 novel coronavirus (2019-nCoV or SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV);

(2) coronavirus causing the common cold: the coronavirus causing the common cold is selected from the group consisting of: Human coronavirus OC43, Human coronvirus 229E, Human coronvirus NL63, and Human coronvirus HKUL;

(3) human respiratory syncytial virus (RSV);

(4) human influenza virus: influenza A virus, influenza B virus and influenza C virus;

(5) flaviviridae virus: hepatitis C virus (HCV), dengue virus (DENV), Zika virus (Zika);

(6) filoviridae virus: Marburg virus (MBV) and Ebola virus (EBV);

(7) coronavirus infecting other mammals: porcine epidemic diarrhea virus (PEDV).

8. The use of Claim 6, wherein the related diseases caused by the viruses are selected from the group consisting of

(D1) common cold, high-risk symptom infection, respiratory tract infection, pneumonia and the complications thereof caused by human coronavirus infection;

(D2) common cold, high-risk symptom infection, respiratory tract infection, pneumonia and the complications thereof caused by human respiratory syncytial virus (RSV) infection;

(D3) common cold, high-risk symptom infection, respiratory tract infection, pneumonia and the complications thereof caused by human influenza virus infection;

(D4) chronic hepatitis C and the complications thereof caused by hepatitis C virus (HCV);

(D5) dengue fever and the complications thereof caused by dengue virus (DENV);

(D6) infection and the complications thereof caused by Zika virus (Zika);

(D7) hemorrhagic fever and the complications thereof caused by Marburg virus (MBV) and Ebola virus (EBV);

(D8) novel coronavirus pneumonia (Corona Virus Disease 2019，COVID-19) caused by SARS-CoV-2 (COVID-19);


(D9) Porcine epidemic diarrhea caused by porcine epidemic diarrhea virus (PEDV);

(D10) any combination of the above diseases.

9. The use of any one of Claims 6 to 8, wherein the active ingredient is the compound of formula (I) according to any one of Claims 2 to 5, or the pharmaceutically acceptable salts thereof or the crystalline hydrate thereof or the solvate thereof or the prodrug thereof.

10. A pharmaceutical composition comprising

(a) first active ingredient, the first active ingredient is a compound of formula (I), and the pharmaceutically acceptable salts thereof or the crystalline hydrate thereof or the solvate thereof or the prodrug thereof:



(I)


wherein,

R_1 is selected from hydrogen, deuterium, cyano, C_{1-6}acyl, C_{2-6}alkenyl, carbamoyl, hydroxymethyl;

R_2 is selected from OR_3, C_{1-6}alkoxy;

R_3 is selected from hydrogen, C_{1-20}alkanoyl, aminoC_{1-20}alkanoyl, (C_{1-6}alkyl)aminoC_{1-6}alkanoyl, C_{1-6}alkoxyC_{1-6}alkyl, α-amino acid, and the carboxy of the α-amino acid is attached to the hydroxyl on the furan ring via ester bond;

R_4 is selected from hydrogen, deuterium, halogen;

R_5 is selected from R_3,  ;

R_6 is selected from amino, hydroxy, NHOH, $NHCOOR_{12}$;

R_7 is selected from hydrogen, deuterium, halogen;

R_8 is selected from hydrogen, deuterium, halogen, cyano;

X is selected from CH_2, CD_2;

R_9 is C_{6-20}aryl;

R_{10} is $C_{1\text{-}18}$alkyl;

R_{12} is $C_{1\text{-}20}$alkyl;

M is each independently selected from hydrogen, metal, or protonated organic amines;

and (b) pharmaceutically acceptable carriers.


11. The pharmaceutical composition of Claim 10, wherein the compound of formula (I) is defined as in any one of Claims 2 to 5.

12. A use of pharmaceutical composition of any one of Claims 10 to 11 in preparing (a) inhibitors that inhibit the replication of coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV); and/or (b) medicaments for treating and/or preventing, alleviating related diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV) infection.

13. A method for inhibiting virus replication, wherein comprises the step of

contacting a first active ingredient or a formulation containing the first active ingredient with a virus, thereby inhibiting the replication of the virus;

wherein the first active ingredient is a compound of formula (I) or the pharmaceutically acceptable salts thereof or the crystalline hydrate thereof or the solvate thereof or the prodrug thereof:



(I)


wherein,

R_1 is selected from hydrogen, deuterium, cyano, $C_{1\text{-}6}$acyl, $C_{2\text{-}6}$alkenyl, $C_{3\text{-}6}$cycloalkyl, carbamoyl, hydroxymethyl;

R_2 is selected from OR_3, $C_{1\text{-}6}$alkoxy;

R_3 is selected from hydrogen, $C_{1\text{-}20}$alkanoyl, amino$C_{1\text{-}20}$alkanoyl, $C_{1\text{-}6}$alkylamino$C_{1\text{-}6}$alkanoyl, $C_{1\text{-}6}$alkoxy$C_{1\text{-}6}$alkyl, α-amino acid, and the carboxyl of the α-amino acid is attached to the hydroxyl on the furan ring via ester bond;

R_4 is selected from hydrogen, deuterium, halogen;

R_5 is selected from R_3,  ;

R_6 is selected from amino, hydroxy, NHOH, $NHCOOR_{12}$;

R_7 is selected from hydrogen, deuterium, halogen, amino, methyl, $NHCOR_{12}$, $NHCOOR_{12}$;

R_8 is selected from hydrogen, deuterium;

X is selected from $-CH_2-$, $-CD_2-$;


R_9 is C_{6-20}aryl;

R_{10} is C_{1-18}alkyl;

R_{12} is C_{1-20}alkyl;

M is each independently selected from hydrogen, metal, or protonated organic amines.

14. A method for (a) inhibiting viral replication and/or (b) treating and/or preventing, alleviating related diseases caused by viral infection, wherein comprises the step of administrating safe and effective amount of a compound of formula (I), or the pharmaceutically acceptable salts thereof or the crystalline hydrate thereof or the solvate thereof or the prodrug thereof to the subject in need thereof:



(I)

wherein, R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8 and X are defined as in Claim 1.